John M. Amatruda
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Diet and metabolism studies, Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, Pharmacology and Obesity Treatment, Diabetes Treatment and Management
Most-Cited Works
- → Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes(2009)304 cited
- → Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes(2008)260 cited
- → Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency(2008)238 cited
- → Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study(2010)202 cited
- → The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake(2008)200 cited
- → Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults(2006)181 cited